Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
卵巣がんの自己抗体バイオマーカー
Document Type and Number:
Japanese Patent JP6588893
Kind Code:
B2
Abstract:
The present invention relates to the identification of biological markers of ovarian cancer. Specifically, cancer-associated autoantibodies to ANXA1, ARP3, SAHH, SERPH, ARAP1, OTUB1, ATP1A1, UBA1, and CFAH have been identified in subjects with early stage ovarian cancer. These autoantibodies can be utilised for a range of purposes including methods for detecting ovarian cancer, methods for screening for early stage ovarian cancer, and methods for assessing treatment response as well as disease progression and recurrence. The autoantibodies also represent prognostic markers of ovarian cancer development.

Inventors:
Peter Hoffman
Martin aurer
Karina Martin
Application Number:
JP2016515521A
Publication Date:
October 09, 2019
Filing Date:
September 18, 2014
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ADELAIDE RESEARCH & INNOVATION PTY LTD
International Classes:
G01N33/564; G01N33/574
Domestic Patent References:
JP2010503845A
JP2008309612A
JP2011257147A
JP2002539175A
JP2003535309A
Foreign References:
US20120004289
US20140179808
Other References:
Hwee,Serum autoantibodies as biomarkers for early cancer detection,FEBS Journal,2009年,Vol.276,Page.6880-6904
Hee Jung An,Comparative proteomics of Ovarian Epithelial Tumors,Journal of Proteome Research,2006年,Vol.5,Page.1082-1090
B Burford,Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung, or pancreatic cancer,British Journal or Cancer,2013年,Vol.108,Page.2045-2055
Attorney, Agent or Firm:
Kenji Sugimura
Koichiro God
Yoshikazu Takagi